Full Press Release Details
SAN DIEGO , May 12, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it will host an Analyst and Investor Day at the New York Palace Hotel in New York City on Thursday May 21, 2015 from 12:00 p.m. to 3:30 p.m. ET ( 9:00 a.m. to 12:30 p.m. PT ).
Presenters will include:
To attend the live event at the New York Palace Hotel, please contact Neurocrine investor relations at [email protected] .
To access the webcast on May 21 , go to the homepage on www.neurocrine.com and click on the Webcasts & Presentations box to access the link. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com .
SOURCE Neurocrine Biosciences, Inc.